Pioglitazone for the treatment of type 2 diabetes

Abstract

Pioglitazon is available on polish market since November 2013 after registration and admission to trading in July 2012. This medicine is a thiazolidinedione belonging to a group of drugs called insulin sensitizers. Pioglitazon may be started as monotherapy oradded as a second or third drug in patients who did not meet the therapy goals even though treated with metformin or metformin combined with other oral antidiabetic drugs or incretinomimetics as well as it can be added to insulin therapy. Pioglitazon is though to have a good influence of cardiovascular risk factors that is why it lowers cardiovascular risk as well as it has renoprotective properties. Pioglitazon’s side effects can be avoided when prescribed with caution.